<DOC>
	<DOCNO>NCT02317445</DOCNO>
	<brief_summary>Objective : To investigate relationship Helicobacter pylorus ( Hp ) infection prognosis acute coronary syndrome ( ACS ) Chinese population explore significance Hp eradication therapy prevent major adverse cardiac event ( MACE ) upper gastrointestinal bleeding ( UGIB ) patient dual antiplatelet treatment . Methods : To analyze 472 ACS patient drug-eluting stent ( DES ) implantation January 1 , 2008 December 31 , 2010 department cardiology Beijing Mentougou District Hospital . Patients divide three group : Group 1 , Hp-negative patient ( Hp- ) ; Group 2 , Hp-positive patient eradication therapy ( Hp+ Therapy ) ; Group 3 , Hp-positive patient without eradication therapy ( Hp+ No Therapy ) . All patient take 13C urea breath test , high sensitive C-reactive protein ( hs-CRP ) ，homocysteine ( HCY ) biochemical indicator . The investigator explore correlation Hp eradication therapy MACE ( include recurrent myocardial infarction , revascularization death ) UGIB 3 5 year follow-up use survival analysis .</brief_summary>
	<brief_title>Relationship Helicobacter Pylori Eradication Therapy Long-term Outcome Acute Coronary Syndrome</brief_title>
	<detailed_description>This study single-center random analysis . The consecutive hospitalized patient ACS Beijing Mentougou District Hospital January 1 , 2008 December 31 , 2010 enrol . Figure 1 flow diagram trial . There 259 male ( 54.9 % ) 213 female ( 45.1 % ) average age 61.1 ± 11.0 year . Patient 's history , physical examination , laboratory result record . All patient divide Hp-negative group ( Hp- , group 1 . ) Hp-positive group ( Hp+ ) . The Hp+ group randomly divide two group : Group 2 , Hp+ eradication therapy ( Hp+ Therapy ) ; Group 3 , Hp+ without eradication therapy ( Hp+No Therapy ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Patients diagnose acute coronary syndrome accord 2012 ESC guidlines . All patient take dual antiplatelet therapy implant drug elute stent ( DES ) hospitalization digestive symptom . Subjects suffer gastrointestinal bleeding within one week . Subjects history gastrectomy , cardiac insufficiency , thyroid dysfunction , ongoing infection eliminate . Patients use antibiotic , bismuth , sucralfate within one month without impanting DES ACS hospitalization also exclude . Those gastrointestinal symptom , acid reflux , heartburn , nausea , vomit , stomach ache diarrhea , confirm peptic ulcer Hp infection exclude patient may take gastroenterology treatment .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>73 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>helicobacter pylorus</keyword>
	<keyword>eradication therapy</keyword>
	<keyword>major adverse cardiac event</keyword>
	<keyword>long-term outcome</keyword>
	<keyword>To explore significance Hp eradication therapy prevent major adverse cardiac event ( MACE ) upper gastrointestinal bleeding ( UGIB ) .</keyword>
</DOC>